AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · Delayed Price · USD
7.77
-0.04 (-0.51%)
At close: Jan 27, 2022 4:00 PM
7.76
-0.01 (-0.13%)
After-hours:Jan 27, 2022 7:57 PM EST
Market Cap2.19B
Revenue (ttm)443.80M
Net Income (ttm)210.52M
Shares Out281.58M
EPS (ttm)0.64
PE Ratio12.07
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,161,898
Open8.05
Previous Close7.81
Day's Range7.62 - 8.05
52-Week Range7.42 - 55.22
Betan/a
AnalystsBuy
Price Target38.88 (+400.4%)
Earnings Daten/a

About ABCL

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.

IndustryBiotechnology
IPO DateDec 11, 2020
Employees360
Stock ExchangeNASDAQ
Ticker SymbolABCL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ABCL stock is "Buy." The 12-month stock price forecast is 38.88, which is an increase of 400.39% from the latest price.

Price Target
$38.88
(400.39% upside)
Analyst Consensus: Buy

News

AbCellera to Report Full Year 2021 Financial Results on February 24, 2022

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Report Full Year 2021 Financial Results on February 24, 2022

14 hours ago - Business Wire

AbCellera Announces Changes to Its Board of Directors

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Announces Changes to Its Board of Directors

1 month ago - Business Wire

AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emer...

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized for Emergency Use in COVID-19 Patients Under the Age of 12

1 month ago - Business Wire

AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer

1 month ago - Business Wire

AbCellera Reports Q3 2021 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q3 2021 Business Results

2 months ago - Business Wire

How Much Upside is Left in AbCellera Biologics Inc. (ABCL)? Wall Street Analysts Think 161%

The consensus price target hints at a 160.5% upside potential for AbCellera Biologics Inc. (ABCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...

2 months ago - Zacks Investment Research

AbCellera Announces Virtual Presentations at Investor Conferences in November

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Announces Virtual Presentations at Investor Conferences in November

2 months ago - Business Wire

Why AbCellera Biologics Stock Sank 21.6% in October

The biotech is now down roughly 56% across 2021's trading.

2 months ago - The Motley Fool

Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Go...

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for COVI...

2 months ago - Business Wire

AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021

3 months ago - Business Wire

Why AbCellera Biologics Stock Jumped 19.4% Last Month

Despite last month's gains, the biotech stock is now down roughly 61% year to date.

3 months ago - The Motley Fool

AbCellera (ABCL), Everest to Co-Develop New Antibody Therapies

AbCellera (ABCL) partners with China-based Everest Medicines to expand the latter???s pipeline across multiple indications.

4 months ago - Zacks Investment Research

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

VANCOUVER, British Columbia and SHANGHAI, Sept. 22, 2021 /PRNewswire/ -- AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a mu...

4 months ago - PRNewsWire

Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab...

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19

4 months ago - Business Wire

AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody

The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in certain individuals to prevent SAR...

Other symbols:LLY
4 months ago - Benzinga

Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to ...

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--EUA of Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19

4 months ago - Business Wire

Why AbCellera Biologics Stock Jumped 7% on Wednesday

The company's drug-development technology is starting to attract attention.

4 months ago - The Motley Fool

AbCellera Shares Are Moving Higher On Licensing Pact With Moderna

AbCellera Biologics Inc (NASDAQ: ABCL) has entered into a research collaboration and license agreement with Moderna Inc (NASDAQ: MRNA) for antibodies for mRNA medicines. The collaboration will leverage ...

Other symbols:MRNA
4 months ago - Benzinga

AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines

4 months ago - Business Wire

AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets

VANCOUVER, British Columbia & BOSTON--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets

4 months ago - Business Wire

AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference

VANCOUVER--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference

4 months ago - Business Wire

Here's Why AbCellera Biologics Stock Gained 10.6% Last Month

Even with its recent gains, the biotech stock is down roughly 53.4% in 2021's trading.

4 months ago - The Motley Fool

Why AbCellera Biologics Stock Was Up More Than 17% on Friday

The biopharma company's second quarter was better than expected. The future looks pretty bright, too.

5 months ago - The Motley Fool

AbCellera Reports Q2 2021 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q2 2021 Business Results

5 months ago - Business Wire

Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?

One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.

Other symbols:ACADFOLDSRPTTGTX
5 months ago - The Motley Fool